arrow
A

Atsuhiko Kawamoto

Nara Medical University
H指数:49
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan ― Insights From the PARACLETE Study ―

日本符合皮下胰高血糖素样肽-1受体激动剂肥胖相关适用标准的射血分数保留的心力衰竭患者的患病率及临床特征——来自PARACLETE研究的见解

2026-04-012
PRE
Prevalence, Characteristics, and Pharmacological Strategies in Patients With Heart Failure With Supranormal Ejection Fraction ― Insights From the PARACLETE Study ―

心力超射射血分数患者的患病率、特征及药物治疗策略——来自PARACLETE研究的研究见解

2025-12-010
PRE
Autologous peripheral blood mononuclear cell-loaded injectable cell scaffold (ICS-001) for revolutionising angiogenic therapy: a study protocol for an exploratory clinical trial
2025-10-230
OA
PS13.3: Exploratory physician-initiated clinical trial for innovative angiogenic therapy using injectable cell scaffold (ICS-001) with peripheral blood mononuclear cells for chronic limb threatening ischemia.

PS13.3: 探索性医生发起的临床试验,针对慢性肢体威胁性缺血的创新血管生成疗法,使用注射用细胞支架(ICS-001)与外周血单核细胞。

2025-10-200
PRE
Hepatic arterial infusion of autologous CD34+cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial
2024-12-012
OAAI
Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3

造血干细胞衰老与心肌修复-冠心病CABG/CD133骨髓造血干细胞治疗RCT完美3期诱导心肌梗死后心肌再生反应的基因型/表型分析

2020-07-0122
OAAI
CD34+ cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis
2014-10-1520
PREAI